Price movement over the last 24 hours
Airbnb, Inc. vs Cassava Sciences Inc — how do they compare? Airbnb, Inc. trades at $142.83 (market cap $88.31B), while Cassava Sciences Inc trades at $1.19 (market cap $63.04M). The key difference: Airbnb, Inc. is far larger — about 1400.9× Cassava Sciences Inc's market cap, and Airbnb, Inc. is trading nearer its 52-week high, Cassava Sciences Inc nearer its low. Which is the better fit depends on your goals.
| ABNB | FLNA | |
|---|---|---|
Market Cap | $88.31B | $63.04M |
Sector | Consumer Cyclical | Health |
52-Week High | $148.93 | $4.64 |
52-Week Low | $111.54 | $1.16 |
Enterprise Value | $78.84B | -$23.53M |
Signals from Pluang's Aura AI — not financial advice
Airbnb (ABNB) trades at $148.80, showing minimal daily movement with a slight decline of 0.09%. The stock maintains a bullish technical outlook with strong moving average signals and trades near pivot point resistance at $149. Fundamentally, the company demonstrates robust profitability with 82.9% gross margins and 19.9% net income margin, though recent quarters have seen earnings misses against expectations. Revenue growth continues with 2025 reaching $12.24 billion, supported by the company's asset-light model and global travel recovery.
The investment case balances strong fundamentals against valuation concerns, with a P/E of 36.5 suggesting premium pricing. Analyst consensus remains positive with a $161.80 price target, though recent earnings misses and CEO stock sales warrant monitoring. Key risks include travel demand sensitivity, competitive pressures, and execution of new initiatives like hotel expansion and AI development. The stock offers growth exposure to travel recovery but requires careful valuation assessment.
FLNA trades at $1.31, up 6.5% today, with a bearish technical signal but recent quarterly earnings beats. The company, focused on therapies for Tuberous Sclerosis Complex-related epilepsy, reported a net loss of $90.97 million in 2025, with negative cash flow from operations. Analyst consensus is bullish with 8 buy ratings out of 12, and recent news highlights business updates and scientific presentations.
The outlook is mixed: strong analyst support and clinical progress offer upside potential, but persistent losses, negative cash flow, and high financial risks pose significant challenges. Investors should weigh the speculative growth prospects against the substantial operational deficits and market volatility.
Trailing returns across standard periods
Latest headlines on both assets
Airbnb, Inc. operates an online marketplace for travel information and booking services. The Company offers lodging, home stay, and tourism services via websites and mobile applications. Airbnb serves clients worldwide.
Read more on ABNB →Cassava Sciences Inc is a clinical-stage biotechnology company engaged in developing a scientific approach for the treatment and detection of Alzheimer's disease. Its therapeutic product candidate is called simufilam, and it is a novel treatment for Alzheimer's disease
Read more on FLNA →